What is Insulet's accrued expenses?

Insulet (PODD) reported accrued expenses of $519M in Q1 2026.

What is the long-term trend for Insulet's accrued expenses?

Over 3 years (2020 to 2025), Insulet's accrued expenses has grown at a 62.0% compound annual growth rate (CAGR), from $138.1M to $586.7M.

Insulet PODD Accrued Expenses

Accrued Expenses at other companies

Eli LillyLLY

$1.36B+22.0%

MedtronicMDT

$3.63B-1.3%

West Pharmaceutical ServicesWST

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

See full

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's accrued expenses?: Insulet (PODD) reported accrued expenses of $519M in Q1 2026.
What is the long-term trend for Insulet's accrued expenses?: Over 3 years (2020 to 2025), Insulet's accrued expenses has grown at a 62.0% compound annual growth rate (CAGR), from $138.1M to $586.7M.